Hospital
New Liberty Hospital District
New Liberty Hospital District was paid $9.93M by Medicaid between Jan 2018 and Nov 2024, across 60 billing codes. Its largest line is X4011, State-specific procedure code — 17% of everything it billed.
33Billing provider infoNEW LIBERTY HOSPITAL DISTRICT
LIBERTY, MO 64068
LIBERTY, MO 64068
33aNPI1811036726assigned 02/06/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.93M
24GClaims93,196
24DCodes billed60
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Missouri
Rank by total paid#27 of 74
Median peer was paid$4.44M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,388 | $3.66M | |
| 2019 | 8,213 | $2.15M | |
| 2020 | 6,968 | $941K | |
| 2021 | 12,209 | $389K | |
| 2022 | 16,196 | $933K | |
| 2023 | 22,085 | $1.30M | |
| 2024incomplete | 10,137 | $558K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| X4011 | State-specific procedure code | 17% | 6,192 | 5,821 | $1.73M |
| Y7506 | 15% | 6,497 | 6,023 | $1.54M | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 12% | 17,423 | 16,192 | $1.14M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 7,466 | 7,065 | $1.10M |
| 80053 | Comprehensive metabolic panel | 7.1% | 16,249 | 15,197 | $710K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.8% | 3,114 | 2,968 | $679K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.4% | 2,263 | 2,127 | $636K |
| 80047 | 4.6% | 1,857 | 1,734 | $456K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.5% | 4,051 | 3,646 | $251K |
| 80076 | 2.5% | 1,042 | 974 | $248K | |
| 71045 | Radiologic examination, chest; single view | 2.1% | 3,523 | 3,321 | $207K |
| 83690 | 1.7% | 3,627 | 3,409 | $172K |
48 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.4% | 868 | $138K |
| 84703 | <1% | 779 | $88K | |
| 85610 | <1% | 2,126 | $75K | |
| 84484 | <1% | 2,306 | $72K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,009 | $70K |
| G0378 | Hospital observation service, per hour | <1% | 274 | $68K |
| 85730 | <1% | 2,112 | $65K | |
| 81001 | <1% | 680 | $65K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,205 | $65K |
| 83880 | <1% | 968 | $41K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 992 | $40K |
| 81003 | <1% | 233 | $39K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 174 | $39K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 85 | $30K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 446 | $29K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 212 | $20K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 420 | $19K |
| 99999 | <1% | 687 | $16K | |
| 82550 | <1% | 416 | $13K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 903 | $12K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 192 | $11K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 220 | $8K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 251 | $8K |
| Y7507 | <1% | 12 | $6K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 13 | $6K |
| X4006 | <1% | 23 | $4K | |
| 83735 | <1% | 652 | $3K | |
| 84702 | <1% | 161 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 82 | $2K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 12 | $927.60 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 26 | $901.07 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $775.70 |
| 83605 | <1% | 101 | $657.92 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 58 | $625.66 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 38 | $517.57 |
| 85379 | <1% | 38 | $346.68 | |
| J3490 | Unclassified drugs | <1% | 210 | $270.00 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 52 | $170.78 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 21 | $150.47 |
| 87040 | <1% | 15 | $137.78 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 67 | $94.50 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 53 | $63.18 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 37 | $55.45 |
| 82962 | <1% | 37 | $10.48 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 75 | $0.00 |
| A9270 | Non-covered item or service | 0% | 491 | $0.00 |
| 96361 | Intravenous infusion, hydration; each additional hour | 0% | 25 | $0.00 |
| 96376 | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLEONE, MICHAEL (CHIEF FINANCIAL OFFICER)